Blood Platelet Disorders: Clinical Trials

194 trials for Blood Platelet Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

102 completed, 35 recruiting, 24 terminated, 11 unknown. 194 Phase 1, 77 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1194Completed 102, Recruiting 35, Terminated 24, Unknown 11, Active not recruiting 8, Withdrawn 7, Not yet recruiting 6, Enrolling by invitation 1
Phase 277Completed 36, Recruiting 14, Terminated 11, Unknown 6, Withdrawn 4, Active not recruiting 3, Not yet recruiting 3

Follow Blood Platelet Disorders: new trials by email Literature Review of Blood Platelet Disorders trials Research Report on Blood Platelet Disorders

Trials (filtered) newest first · largest first

All 194 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias
RXIM002 - Immune Thrombocytopenia (ITP)
Phase 1Not yet recruitingRiboX Therapeutics Ltd.272027-02-012026-10-28
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV)
Phase 1 / Phase 2Not yet recruitingUniversity Hospital Tuebingen362027-01-012026-11-12
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 1 / Phase 2Not yet recruitingCullinan Therapeutics Inc.722026-12-012026-07-31
TGD001 Treatment in Thrombotic Microangiopathies
TGD001 - Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
Phase 1 / Phase 2RecruitingTargED Biopharmaceuticals B.V.702026-10-252026-11-12
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs)
Phase 1RecruitingDamora Therapeutics2502026-09-012026-10-27
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia
Phase 1 / Phase 2RecruitingCRISPR Therapeutics AG602026-07-172026-10-20
Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions
SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules - Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP)
Phase 1Active not recruitingOscotec Inc.482026-07-102026-09-01
A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia
JCXH-213 - Thrombocytopenic Purpura, Immune
Phase 1RecruitingThe General Hospital of Western Theater Command42026-06-182026-11-17
CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia
Anti-CD20 monoclonal antibody and the BTK inhibitor - Anti-CD20 Monoclonal Antibody, BTK Inhibitors
Phase 1Not yet recruitingQi deng302026-06-012026-05-22
Therapeutic RSK1 Targeting in Myeloid Malignancies
PMD-026 - Myeloid Malignancy
Phase 1RecruitingWashington University School of Medicine302026-05-202026-10-21
Universal STAR-T Cell Injection in R/R Autoimmune Diseases.
Universal STAR-T Cell - Immune Thrombocytopenia
Phase 1Not yet recruitingJian Zhu62026-05-112026-05-20
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms
Phase 1RecruitingIncyte Corporation2182026-05-112026-11-13
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
ZE74-0282-0001 or placebo - Healthy Volunteers
Phase 1RecruitingEilean Therapeutics AU Pty Ltd642026-04-162026-07-28
Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia
GL-2045 - Immune Thrombocytopenia
Phase 1RecruitingGliknik Inc.422026-04-142026-05-26
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
CM336 Injection - Autoimmune Cytopenia, Immune Thrombocytopenia (ITP)
Phase 1 / Phase 2RecruitingKeymed Biosciences Co.Ltd1582025-11-182025-12-17
Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
SHR-2173 Injection - Immune Thrombocytopenia
Phase 1RecruitingGuangdong Hengrui Pharmaceutical Co., Ltd102025-11-122026-05-28
An Exploratory Study of Golidocitinib in Adult Patients With ITP
Golidocitinib, Placebo - Immune Thrombocytopenia (ITP)
Phase 1 / Phase 2Not yet recruitingPeking University People's Hospital1382025-10-302025-09-29
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
INCA035784 - Myeloproliferative Neoplasms
Phase 1RecruitingIncyte Corporation1202025-10-012026-08-06
Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)
Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) - Thrombocytopenia, Cancer
Phase 1RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences162025-08-282025-09-09
OM336 in Autoimmune Cytopenias
OM336 - AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
Phase 1RecruitingLakefront Biotherapeutics West LLC322025-08-012026-09-03

Showing 20 of 194. Sign in to see all of them.

Narrower conditions

Thrombocythemia, Essential (68)  ·  Primary Myelofibrosis (67)  ·  Purpura, Thrombocytopenic, Idiopathic (63)  ·  Polycythemia Vera (59)  ·  Myeloproliferative Disorders (58)  ·  Thrombocytopenia (49)  ·  Leukemia, Myeloid, Acute (44)  ·  Leukemia, Myelomonocytic, Chronic (40)  ·  Myelodysplastic Syndromes (38)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (35)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (33)  ·  Leukemia (32)  ·  Multiple Myeloma (28)  ·  Lymphoma, Non-Hodgkin (27)  ·  Burkitt Lymphoma (26)

Broader conditions

Hemic and Lymphatic Diseases (194)  ·  Hematologic Diseases (184)  ·  Hemorrhagic Disorders (144)  ·  Blood Coagulation Disorders (142)  ·  Pathological Conditions, Signs and Symptoms (129)  ·  Pathologic Processes (128)  ·  Cytopenia (109)  ·  Immune System Diseases (109)  ·  Bone Marrow Diseases (80)  ·  Neoplasms (76)  ·  Neoplasms by Site (67)  ·  Signs and Symptoms (67)  ·  Hemorrhage (66)  ·  Skin Manifestations (65)

Interventions

eltrombopag (15)  ·  ruxolitinib (12)  ·  Peripheral Blood Stem Cell Transplantation (11)  ·  Cyclosporine (9)  ·  fludarabine phosphate (7)  ·  Busulfan (6)  ·  Carboplatin (6)  ·  Cyclophosphamide (6)  ·  Filgrastim (6)  ·  Antilymphocyte Serum (5)  ·  Cytarabine (5)  ·  Decitabine (5)  ·  Etoposide (5)  ·  romiplostim (5)  ·  Methotrexate (4)

Sponsors

National Cancer Institute (NCI) (9)  ·  GlaxoSmithKline (7)  ·  Incyte Corporation (6)  ·  Eisai Inc. (5)  ·  Amgen (4)  ·  Chongqing Peg-Bio Biopharm Co., Ltd. (4)  ·  Eli Lilly and Company (4)  ·  Fred Hutchinson Cancer Center (4)  ·  Peking University People's Hospital (4)  ·  M.D. Anderson Cancer Center (3)  ·  National Heart, Lung, and Blood Institute (NHLBI) (3)  ·  Protalex, Inc. (3)  ·  Bioverativ, a Sanofi company (2)  ·  California Cancer Consortium (2)  ·  Case Comprehensive Cancer Center (2)

Countries

United States (124)  ·  China (35)  ·  United Kingdom (22)  ·  Australia (19)  ·  Germany (17)  ·  Italy (17)  ·  France (15)  ·  Spain (15)  ·  Canada (13)  ·  Belgium (8)  ·  Netherlands (7)  ·  Poland (7)  ·  Austria (6)  ·  Denmark (6)  ·  Japan (6)

Top investigators

Ayalew Tefferi, MD (2)  ·  Brenda Cooper, MD (2)  ·  Franklin Johnson (2)  ·  Jacob H Grauslund, MD (2)  ·  Jorge Cortes, MD (2)  ·  Qiubai Li, Professor (2)  ·  Richard K. Burt, MD (2)  ·  Ronald Hoffman, MD (2)

Results publications

PMID 15570084, PMID 15814645, PMID 17880439, PMID 19208097, PMID 19846889, PMID 20843246, PMID 20955619, PMID 22259028, PMID 22718840, PMID 23131255, PMID 23497336, PMID 23777763, PMID 23829485, PMID 24120380, PMID 24474568, PMID 24802773, PMID 25563429, PMID 25621498, PMID 25762180, PMID 26210442, PMID 26354756, PMID 26504182, PMID 26686043, PMID 26853648, PMID 27479177, PMID 27515248, PMID 28934680, PMID 29270980, PMID 29419434, PMID 29544547, PMID 29674506, PMID 29958797, PMID 30171280, PMID 30204953, PMID 30344993, PMID 30562587, PMID 31167802, PMID 32476546, PMID 32634234, PMID 32865293, PMID 33410523, PMID 33718228, PMID 33910334, PMID 34219224, PMID 34452956, PMID 34525188, PMID 34724566, PMID 34921514, PMID 35973190, PMID 36881782

NIH funding

2018 (4), 2014 (2), 2023 (2), P30CA015083 (2), P30CA016058 (2), U01CA062491 (2), 2005 (1), 2019 (1), 2025 (1), P01CA015396 (1), P01CA018029 (1), P01CA108671 (1), P30CA006973 (1), P30CA016086 (1), P30CA016087 (1)